Compare ARAY & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | BTMD |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6M | 64.4M |
| IPO Year | 2006 | 2021 |
| Metric | ARAY | BTMD |
|---|---|---|
| Price | $0.41 | $1.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $3.50 | $2.25 |
| AVG Volume (30 Days) | ★ 1.3M | 203.3K |
| Earning Date | 04-29-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 87.50 | ★ 722.22 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $192,219,000.00 |
| Revenue This Year | N/A | $4.11 |
| Revenue Next Year | $4.58 | $8.50 |
| P/E Ratio | ★ N/A | $1.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $1.35 |
| 52 Week High | $2.10 | $4.75 |
| Indicator | ARAY | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 30.79 | 16.26 |
| Support Level | N/A | N/A |
| Resistance Level | $0.63 | $2.76 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 29.99 | 1.81 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.